Release Testing for Gene Therapy Market Report 2026

The release testing for gene therapy market size has grown rapidly in recent years. It will grow from $1.43 billion in 2025 to $1.67 billion in 2026 at a compound annual growth rate (CAGR) of 16.3%. The growth in the historic period can be attributed to rise in gene therapy trials, strict regulatory quality standards, growth in viral vector production, expansion of biologics testing labs, increase in advanced therapy approvals.

The release testing for gene therapy market size is expected to see rapid growth in the next few years. It will grow to $3.08 billion in 2030 at a compound annual growth rate (CAGR) of 16.5%. The growth in the forecast period can be attributed to growth in commercial gene therapies, rising demand for rapid release testing, expansion of contract testing services, increasing regulatory scrutiny, adoption of automated qc platforms. Major trends in the forecast period include high sensitivity potency assays, rapid sterility testing platforms, automated batch release analytics, multi parameter quality control panels, advanced vector identity testing.

The rising number of global approvals for gene therapies is expected to fuel the growth of the release testing for gene therapy market going forward. Gene therapies are medical treatments that involve the introduction, removal, or modification of genetic material within a patient’s cells to treat or prevent disease. Growth in global gene therapy approvals is supported by increasing regulatory acceptance, ongoing scientific advancements, and rising demand for innovative treatments targeting previously untreatable genetic disorders. Release testing for gene therapy is a regulatory requirement that ensures product quality and patient safety through evaluations of potency, purity, identity, and safety prior to batch release. For instance, in November 2023, according to the National Center for Biotechnology Information, a U.S.-based governmental research resource, more than 100 gene, cell, and ribonucleic acid (RNA) therapies had been approved globally as of early 2023, with over 3,700 additional therapies in clinical and preclinical development. Therefore, the increasing number of global gene therapy approvals is expected to support the growth of the release testing for gene therapy market.

Leading companies operating in the release testing for gene therapy market are focusing on developing innovative solutions, such as digital PCR-based analytical testing platforms, to address the growing need for highly accurate, sensitive, and standardized methods that ensure product safety, potency, and regulatory compliance for complex gene therapy products. Digital polymerase chain reaction (PCR)-based analytical testing platforms are advanced molecular systems that precisely quantify deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) by partitioning samples into thousands of individual reactions, enabling highly sensitive and absolute measurement of nucleic acid targets. For example, in April 2025, QIAGEN N.V., a Germany-based provider of molecular diagnostics and life science tools, expanded its QIAcuity digital PCR portfolio with new lentivirus solutions designed to enhance quality control in cell and gene therapy manufacturing. These additions support viral vector genome titration, vector copy number determination, and replication-competent lentivirus detection, enabling high-precision analytics for process development, batch release, and regulatory compliance. The platform offers absolute quantification across singleplex and multiplex applications, strong repeatability, and tailored kits for critical gene therapy vectors, providing more reliable and reproducible results than many conventional testing approaches.

In January 2026, bioMérieux S.A., a France-based biotechnology company, acquired Accellix Inc. for approximately $41 million (€35 million). With this acquisition, bioMérieux aimed to strengthen and expand its pharmaceutical quality control portfolio particularly in rapid, automated flow cytometry solutions for cell and gene therapy manufacturing to support the growing advanced therapies market and improve testing capabilities across the therapy development lifecycle. Accellix Inc. is a US-based quality control technology provider that enables rapid, automated flow cytometry-based release testing for cell and gene therapies, specifically supporting critical release parameters such as cell purity and viability.

Major companies operating in the release testing for gene therapy market are Thermo Fisher Scientific Inc., Boehringer Ingelheim BioXcellence GmbH, Fujifilm Diosynth Biotechnologies Inc., AGC Biologics Inc., SGS SA, Lonza Group AG, Eurofins Scientific SE, WuXi AppTec Co. Ltd., Charles River Laboratories International Inc., Sartorius AG, Samsung Biologics Co. Ltd., Bio-Rad Laboratories Inc., Pace Analytical Services LLC, KBI Biopharma Inc., BioAgilytix Labs LLC, Viralgen Vector S.L., GenScript ProBio LLC, KCAS Bioanalytical Services, Creative Biolabs LLC, Cellipont Bioservices Inc.

Tariffs are impacting the release testing for gene therapy market by increasing the cost of imported assay kits, analytical instruments, and specialized reagents. Higher duties are raising operational costs across potency, purity, and safety testing segments. Contract research organizations and biotech manufacturers that depend on imported testing systems are most affected. Regions relying on global laboratory equipment supply chains, especially in asia pacific and europe, are experiencing procurement delays. Testing providers are moving toward regional suppliers and localized sourcing strategies. Tariffs are also encouraging domestic production of test kits and analytical tools. This supports local laboratory supply ecosystems and strengthens long term testing capacity.

The release testing for gene therapy market research report is one of a series of new reports that provides release testing for gene therapy market statistics, including release testing for gene therapy industry global market size, regional shares, competitors with a release testing for gene therapy market share, detailed release testing for gene therapy market segments, market trends and opportunities, and any further data you may need to thrive in the release testing for gene therapy industry. This release testing for gene therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Release testing for gene therapy is a quality assurance procedure performed to verify that gene therapy products meet established safety, effectiveness, purity, and identity requirements before patient use. It ensures that gene therapy treatments are safe, reliable, and compliant with regulatory standards for clinical and commercial application.

The primary types of release testing for gene therapy include potency testing, purity testing, identity testing, safety testing, sterility testing, and other test types. Potency testing refers to procedures used to evaluate the biological activity of gene therapy products to ensure effectiveness and consistency. These tests are conducted for product types including assay kits, reagents, instruments, and services. They are used for therapy types such as in vivo gene therapy and ex vivo gene therapy. They are applied across applications including clinical diagnostics, research, quality control, process development, and other applications, and are utilized by end users including pharmaceutical and biotechnology companies, academic and research institutes, contract research organizations (CROs), and other end users.

The release testing for gene therapy market includes revenues earned by entities through the quality control and analytical testing services, stability assessment, method validation, regulatory compliance testing, and batch release support. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.